利拉鲁肽降低超重和肥胖患者体质量有效性和安全性的系统评价
x

请在关注微信后,向客服人员索取文件

篇名: 利拉鲁肽降低超重和肥胖患者体质量有效性和安全性的系统评价
TITLE:
摘要: 目的:系统评价利拉鲁肽降低超重和肥胖患者体质量的有效性和安全性,为临床提供循证参考。方法:计算机检索Medline、EMBase、中文科技期刊数据库、万方数据库和中国期刊全文数据库,收集利拉鲁肽对比安慰剂治疗超重和肥胖患者的随机对照试验(RCT),对符合纳入标准的研究进行资料提取和质量评价,采用Rev Man 5.1.0统计软件进行Meta分析。结果:共纳入8项RCT,合计3 560例患者。Meta分析结果显示,利拉鲁肽组患者的体质量减少值[MD=-1.71,95%CI(-2.25,-1.17),P<0.001]和减重>5%的患者占总体的比例[RR=2.20,95%CI(1.83,2.63),P<0.001] 均显著优于对照组;而利拉鲁肽组恶心、呕吐、腹泻、轻中度低血糖、外周水肿发生率显著高于对照组。结论:利拉鲁肽对超重和肥胖患者减重治疗疗效较好,且不良反应较轻微,但其胃肠道不良反应发生率较高,应警惕。
ABSTRACT: OBJECTIVE: To systematically review the effectiveness and safety of liraglutide in the body mass loss of patients with overweight and obesity, and provide evidence-based reference for clinical treatment. METHODS: Retrieved from Medline, EMBase, CJFD, Wanfang and VIP, randomized controlled trials (RCT) about liraglutide versus placebo in the treatment of overweight and obesity were collected. Meta-analysis was performed by using Rev Man 5.1.0 software after data extract. RESULTS: Totally 8 RCTs were enrolled, involving 3 560 patients. Results of Meta-analysis showed weight loss degree [MD=-1.71, 95%Cl (-2.25,-1.17), P<0.001] and the percentage of proportion loss more than 5% to total patients [RR=2.20,95%CI(1.83, 2.63),P<0.001] in liraglutide group were significnatly more than blank control group; while the incidences of nausea, vomiting, diarrhea, mild-to-moderate hypoglycemia and peripheral edema were significantly higher than control group. CONCLUSIONS: Liraglutide is effective for overweight and obesity patients. And there is mild adverse reactions but high incidence of gastrointestinal adverse reactions, which should be vigilant.
期刊: 2016年第27卷第21期
作者: 魏春燕,吴斌,苏娜,徐珽
AUTHORS: WEI Chunyan,WU Bin,SU Na,XU Ting
关键字: 利拉鲁肽;超重;肥胖;体质量;降低;Meta分析
KEYWORDS: Liraglutide; Overweight; Obesity; Body mass; Decrease; Meta-analysis
阅读数: 230 次
本月下载数: 2 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!